Thomas Cahill, M.D., Ph.D.

Thomas Cahill, M.D., Ph.D. is the founder and managing partner of Newpath Partners, a life science venture firm with a mission to translate groundbreaking scientific discoveries into transformative treatments for patients. Under Dr. Cahill’s leadership, Newpath creates and builds most of its portfolio companies by partnering with successful academic and entrepreneurial scientists at the earliest stage to align their interests with investors, management teams, and employees. In addition to Autobahn, Dr. Cahill is a director at Chroma Medicine, Exo Therapeutics, Kisbee Therapeutics, Magnet Biomedicine, Myeloid Therapeutics, Nvelop Therapeutics, Prime Medicine (PRME), and YourBio Health. Prior to Newpath, he worked at the Raptor Group, where he furthered established and led the life science/healthcare and technology investment portfolio. Dr. Cahill received both his M.D. and Ph.D. from Duke University and his M.S. in Chemistry from Stanford University.